Table 4.
Association between VTE and mortality in US veterans diagnosed with MM between July 1, 2006, and June 30, 2014
| 6‐mo mortality | 12‐mo mortality | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| VTE (time varying) | 2.37 | 1.56‐3.60 | <.001 | 1.69 | 1.21‐2.36 | <.001 |
| Year of diagnosis | 0.94 | 0.89‐0.98 | .01 | 0.95 | 0.92‐0.99 | .02 |
| BMI | ||||||
| < 18.5 | 1.70 | 1.10‐2.63 | .02 | 1.49 | 1.01‐2.21 | .05 |
| 18.5‐25 | Referent | Referent | ||||
| 25‐30 | 0.75 | 0.61‐0.93 | .01 | 0.74 | 0.62‐0.89 | .001 |
| ≥ 30 | 0.72 | 0.57‐0.92 | .01 | 0.78 | 0.64‐0.94 | .01 |
| Age (per y increase) | 1.01 | 1.00‐1.02 | .03 | 1.01 | 1.00‐1.02 | .07 |
| Race | ||||||
| Non‐Black | Referent | Referent | ||||
| Black | 0.84 | 0.69‐1.02 | .08 | 0.75 | 0.64‐0.89 | <.001 |
| Charlson Comorbidity Index, per point | 1.07 | 1.04‐1.10 | <.001 | 1.07 | 1.04‐1.09 | <.001 |
| Baseline laboratory data | ||||||
| Hemoglobin < 10 g/dL | 1.17 | 0.97‐1.41 | .11 | 1.15 | 0.99‐1.35 | .07 |
| CrCl < 30 mL/min | 1.50 | 1.23‐1.83 | <.001 | 1.30 | 1.09‐1.54 | <.001 |
| Albumin ≤ 3 g/dL | 1.70 | 1.41‐2.05 | <.001 | 1.60 | 1.36‐1.87 | <.001 |
| Albumin unknown | 0.59 | 0.39‐0.89 | .01 | 0.60 | 0.43‐0.82 | <.001 |
| Myeloma‐specific therapy | ||||||
| Transplant | NE | 0.05 | 0.02‐0.16 | <.001 | ||
| Thalidomide | 0.49 | 0.37‐0.63 | <.001 | 0.52 | 0.42‐0.64 | <.001 |
| Bortezomib | 0.91 | 0.73‐1.14 | .42 | 0.88 | 0.74‐1.05 | .16 |
| Lenalidomide | 0.43 | 0.32‐0.57 | <.001 | 0.46 | 0.38‐0.56 | <.001 |
| Number of therapies in first regimen | 0.71 | 0.59‐0.84 | <.001 | 0.84 | 0.73‐0.97 | .01 |